EUVIMEDEUVIMED entdecken
Crossref

Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system

Qian Liu, Yang Wang, Panwei Hu, Peizhi He

Drug Discoveries & Therapeutics · 2025

DOI: 10.5582/ddt.2025.01043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Discoveries & Therapeutics, 2025. Verfasst von Qian Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Adalimumab, Antibodies, Monoclonal, Humanized, Ustekinumab, Etanercept. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabAntibodies, Monoclonal, HumanizedUstekinumabEtanerceptAbortion, SpontaneousHumansFemalePregnancyAdverse Drug Reaction Reporting SystemsPharmacovigilanceUnited StatesUnited States Food and Drug AdministrationAdultRetrospective StudiesDrug InteractionsDatabases, FactualYoung Adult

Stichwörter der Autor:innen

FAERSbiologicsdisproportionality analysispharmacovigilancespontaneous abortion

Substanzen

AdalimumabAntibodies, Monoclonal, HumanizedUstekinumabEtanerceptdupilumab

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Reproductive Medicine Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Zitieren

APA

Liu, Q., Wang, Y., Hu, P., & He, P. (2025). Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system. Drug Discoveries & Therapeutics. https://doi.org/10.5582/ddt.2025.01043

Vancouver

Liu Q, Wang Y, Hu P, He P. Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system. Drug Discoveries & Therapeutics. 2025. doi:10.5582/ddt.2025.01043

BibTeX
@article{Liu2025,
  author = {Liu, Qian and Wang, Yang and Hu, Panwei and He, Peizhi},
  title = {Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system},
  journal = {Drug Discoveries & Therapeutics},
  year = {2025},
  doi = {10.5582/ddt.2025.01043}
}
Kostenlos starten →